REG - Adv Medical Solutns. - Annual Report and Notice of Annual General Meeting

Advanced Medical SolutionsAnnouncement

13/05/2024 18:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240513:nRSM2449Oa&default-theme=true

RNS Number : 2449O  Advanced Medical Solutions Grp PLC  13 May 2024

13 May 2024

Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

 

Annual Report and Notice of Annual General Meeting

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, is pleased to
announce that its Annual Report and Accounts for the year ended 31 December
2023 and Notice of Annual General Meeting ("AGM") have today been sent to
shareholders.

 

The Annual Report and Accounts is available on the Investor Relations section
of the Company's website https://admedsol.com/Investor-Relations.

 

The AGM will be held at 11:00 a.m. at the offices of Investec Bank plc, 30
Gresham Street, London, EC2V 7QN on 12 June 2024.

 

A copy of the proxy form for the AGM and Notice of AGM are available on the
Company's website
https://admedsol.com/investor-relations/shareholder-information/agm
(https://admedsol.com/investor-relations/shareholder-information/agm) .

 

 

- End -

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc            Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 ICR Consilium                                   Tel: +44 (0) 20 3709 5700
 Mary-Jane Elliott / Lucy Featherstone           AMS@consilium-comms.com

 Investec Bank PLC (NOMAD & Broker)              Tel: +44 (0) 20 7597 5970
 Gary Clarence / David Anderson

 HSBC Bank plc (Broker)                          Tel: 44 (0) 20 7991 8888
 Sam McLennan / Joe Weaving / Stephanie Cornish

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand(®), RESORBA(®),
LiquiBandFix8(®) and Seal-G(®). AMS also supplies wound care dressings such
as silver alginates, alginates and foams through its ActivHeal(®) brand as
well as under white label. Since 2019, the Group has made six acquisitions:
Sealantis, an Israeli developer of innovative internal sealants; Biomatlante,
a French developer and manufacturer of surgical biomaterials, Raleigh, a
leading UK coater and converter of woundcare and bio-diagnostics materials,
AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish
tissue adhesives specialist, and Syntacoll, a German specialist in
collagen-based absorbable surgical implants.

 

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the
Czech Republic and Israel, are sold globally via a network of multinational or
regional partners and distributors, as well as via AMS's own direct sales
forces in the UK, Germany, the Czech Republic and Russia. The Group has
R&D innovation hubs in the UK, Ireland, Germany, France and Israel.
Established in 1991, the Group has more than 900 employees. For more
information, please see  www.admedsol.com (http://www.admedsol.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAAJMFTMTABBMI